Substitute Form PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office

Attorney Docket No. Application No. 25142-0002001 10/797,903 Applicant

Group Art Unit

## Information Disclosure Statement by Applicant (Use several sheets if necessary)

Yamamoto et al.

Filing Date March 10, 2004

(37 CFR §1.98(b))

Examiner Initial	Desig		U.S. Pa	tent Documents		1628	
AP	1	Number	Date	Patentee			Filing Date
1	<del> </del>	5,624,937	04-1997	Reel et al.	Class	Subclass	If Appropria
	2	5,658,374	08-1997	Glover			
	3	6,534,535	03-2003				
	4	6,821,987	11-2004	Zhu et al.			
	5	7,612,092	11-2009	Kubo et al.			
	6	7,612,208		Funahashi et al.			
	7	2004/0053908	11-2009	Matsushima et al.	1		
	8	T	03-2004	Funahashi et al.	<del> </del>		
	9	2004/0242506	12-2004	Barges Causeret et al.	<del> </del>		·
		2004/0253205	12-2004	Yamamoto et al.			
	10	2005/0187236	08-2005	Tsuruoka et al.			
	11	2006/0004029	01-2006	Tsuruoka et al.			
	12	2006/0057195	03-2006				
	13	2007/0004773	01 2007	Nonomura et al.			
	14	2007/0027318	02.2025	Sakaguchi et al.			
		2007/000	02 2007	Kubo et al.			
1		1007/0075		Vaito et al.			
P		007/01/		Matsushima			
<del>-</del>		007/0117842	05-2007 A	rimoto et al.			
Fo	reian F	Patont D	mente e- D				

Examiner Initial	Desig. ID	Document Number	Publication Date	Published Foreign I	Patent A	Applicatio	ns	
1	18	2 253 848	09-1992	Patent Office GB	Class	Subclass	Translat	tion
	19	WO 00/43384	07-2000	WO	<del> </del>			
+	20	WO 00/44728	08-2000	WO				
+		WO 00/47212	08-2000	WO				
<del>  -</del>		WO 00/50405	08-2000	WO				
ho	23	WO 00/71097	11-2000	WO				
	24	WO 02/16348	02-2002	WO			Abst.	

Examiner Signature	
EXAMINER: Initials of the initial of the	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant.	ot in conformance and not considered 1. 2010.
	include copy of this form with

Substitute Form PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office

Attorney Docket No. 25142-0002001

Application No. 10/797,903

Information Disclosure Statement
by Applicant
(Use several sheets if necessary)

Applicant

Yamamoto et al.

Filing Date March 10, 2004

Group Art Unit 1628

(37 CFR §1.98(b))

Exami Initia	ner   De	esig. ID	Docume Number	ent	Publica	tion	rubils	Country	eign	Patent	Ap	plicatio	ns	
100	,	25		<del></del>	Date	}		Country of Patent Off	or ice	J			Trar	nslatio
	<del></del>		WO 03/13		02-2003		WO			Class	<u> </u>	ubclass	Yes	N
		26	WO 04/350		04-2004		WO			<del> </del>	-			
		27	WO 04/647	i	08-2004		WO		<del>-</del>	<del> </del>	<u> </u>		Abst,	
		28	WO 05/447	88	05-2005		WO			<del> </del>	-			
		29	WO 06/308	26	03-2006		WO						Abst.	
		30	WO 06/1374	74	12-2006		WO					_	Abst.	<del> </del> -
		31	WO 96/3914		12-1996		<del> </del>						Abst.	
	= = = = = = = = = = = = = = = = = = = =	32	WO 92/2064		11-1992		WO	·						
	3	-	WO 95/1575	—┼	06-1995		WO							
	3		WO 95/1977		)7-1995		WO							
	3.		WO 96/0929		3-1996		WO						<del></del>	
	3(		VO 96/26997	<del>-   -</del>		_	WO							
	37		VO 96/40142		9-1996		WO			-				
	38		O 97/03069		2-1996		WO							
	39		O 97/13760	╼╁╼╼	1-1997	'	WO							
	40	<del>-   ``</del>			-1997	1	WO							
	41	<del></del>	O 97/13771	04	-1997	V	VO							
	42		O 97/21437	06	-1997	$ \sqrt{V}$	VO							
	<del></del> -		O 97/38984	10-	1997	W	/O							
	43	T	O 98/00134	01-	1998	W	'O							
	44		98/02434	01-	1998	W	O							
+	45		98/02437	01-3	1998	W	0							
	46		98/02438	01-1	998	Wo								
	47	WO	98/13350	04-1	998	W								
+	48	WO	98/23613	06-1	998	WC			-					
-	49	WO	98/32436	07-19	998	WC							-	
	50	WO	30/502	11-19		WO							-	_
	51	WO 9	0/55	11-19										$\dashv$
ner Signatu						WO	<u>-</u>						<del></del>	

Examiner Signature		
	Date Considered	
Dext communication considered	Draw line through citation if not in conformance and	Sayland
communication to a plicant.	and in conformance and i	not considered Include
		Substitute copy of this form with

Substitute Form PTO-1449 Sheet 3 of 5U.S. Department of Commerce Patent and Trademark Office (Modified) Attorney Docket No. Application No. 25142-0002001 Information Disclosure Statement 10/797,903 Applicant by Applicant
(Use several sheets if necessary) Yamamoto et al. Filing Date (37 CFR §1.98(b)) Group Art Unit March 10, 2004 1628

Exam Initia	iner   al	Des	ig. Docume	nt Publica	tion	Published Foreign	Patent /	Application	ons	
1	0		- i duilibe	Date	9	Country or Patent Office			Translation	
-A			52 WO 99/321			WO	Class	Subclass	Yes	No
	<del></del> -		3 WO 99/321	11 07-1999		WO				
		5	4 WO 99/351	32 07-1999		WO	+			
		5	5 WO 99/436:	54 09-1999		WO	+			
-		5	6 0 405 425	08-1998		EP				
		57	7 0 602 851	10-1996		EP	<del> </del>			
+-		58	0 684 820	08-2001		EP				
		59	0 795 556	09-1997		EP		<u></u>		
		60	0 837 063	04-1998	<del>-</del>	EP				
+	<u> </u>	61	1 029 853	02-2004		EP				
<del> </del>	<del>-  </del> -	62	1 797 881	04-2009	<del></del>	EP				
ļ	<del></del>	63	2001-131071	05-2001	<del> -</del> -	JP				
		64	2002-003365	01-2002	<del></del>	IP			Abst.	
		65	2003-026576	01-2003	<del>-  </del> -	P			Abst.	
		66	2004-155773	06-2004		P			Abst.	
		67	2005-501074	01-2005	$ \frac{1}{J}$				Abst.	
		68	1022874	01-1989	JI				Abst.	
	<u> </u>	69	11-143429	05-1999	- Jr			<i>F</i>	Abst.	
		70	11-501343	02-1999	JP			A	bst.	
	ļ	71	4341454	11-1992	JP			A	bst.	
		72	7-176103	07-1995	JP			A	bst.	
		73	8-045927	02-1996	JP			A	bst.	
<del>-</del>	7	74	63-028427	02-1988	JP			Al	ost.	-
	7	5	2006-515884	06-2006	JP			Al	ost.	
			Cumente (in		1 "1			Ab	st.	

	Other Doc	Imanta (:			Aost,
	Examiner Desig	inents (include Aut	hor, Title, Date, and Pla		- <del></del> -
Į	Initial ID		s, sato, and Fig	ace of Publicatio	n)
			Document		
ſ	Examiner Signature				

Examiner Signature	
Date Considered	
EXAMINER: Initials citation considered Drawling	_
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with	 
with the state of	

Substitute Form PTO-1449 Sheet <u>5</u> of <u>5</u> U.S. Department of Commerce Patent and Trademark Office (Modified) Attorney Docket No. Application No. 25142-0002001 Information Disclosure Statement 10/797,903 Applicant by Applicant
(Use several sheets if necessary) Yamamoto et al. Filing Date (37 CFR §1.98(b)) Group Art Unit March 10, 2004 1628

Examiner Initial	Desig.	Documents (include Author, Title, Date, and Place of Publication)
ากเลา	ID_	——————————————————————————————————————
10		Myers et al., "The Preparation and SAR of 4-(Anilino), 4-(Phenoxy), and 4-(Thiophenoxy)-  Quinazolines: Inhibitors of p56 <sup>lck</sup> and EGF-R Tyrosine Kinase Activity." Pi
Ab	91	Quinazolines: Inhibitors of n56 lck and FGH and FGH (Anilino), 4-(Phenoxy), and 4-(Thiophenous)
	<del></del>	- 1 - 2 - 2 - 4 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 2 - 2 - 2
ì	1	
1	92	Effects on Growth of Ham To Novel VEGF Recentor Tyroging Viv.
		Nakamura et al., "E7080(ER-203492-00), a Novel VEGF Receptor Tyrosine Kinase Inhibitor-II.  Effects on Growth of Human Tumor Xenografts and Life Span of Mice in Colon 38 Orthotopic  Nuclei et al. "Sent Lett." Abstract # 52, AACR, Toronto, Canada, April 5.0, 2006
-	02	Transplantation Model," Abstract # 52, AACR, Toronto, Canada, April 5-9, 2003
	93	Nugiel et al., "Synthesis and Evaluation of Indenopyrazoles as Cyclin-Dependent Kinase Inhibitor Taguchi et al., "A royal and Evaluation," J Med Chem. 2002, 45(24):5224, 5222
		Taguchi et al. "A Substituent Pattern," J Med Chem. 2002, 45(24), 522 in Kinase Inhibitor
	94	2. Probing the Ideno Ring Substituent Pattern," J Med Chem, 2002, 45(24):5224-5232  Taguchi et al., "A novel orally active inhibitor of VEGF receptor tyrosine kinases KRN951: Anti- 45:1070-1071. Abstract 2575
		45:1070 1071 At A 1070 1071 At 1 1070 1071 1071 At 1 1070 At
Ţ		angiogenic and anti-tumor activity against human solid tumors," <u>Proc Am Assoc Cancer Res</u> , 2004  Takano et al., "Thermal and in the state of the st
	95	
		Takano et al., "Thermal recording materials with improved background stability," CAPLUS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, 1996, XP002443195
[ ]		**************************************
1 1	70	2005 Court Receptor-2 Tyrosine Kinase Inhibitor found. Wascular Endothelial
		2005, 0.0 IUlia (xu 4400
1 1		
	9/	Yamamoto et al., "E7080 (ER-203492-00), a Novel VEGF Receptor Tyrosine Kinase Inhibitor-III.
	00	Yamamoto et al., "E7080 a Novel Multitargeted Tyrosine Kinase Inhibitor, has direct anti-tumor EL. March 27-31, 2004
· ' 1	98	efficacy via inhibition of KIT signaling in and I yrosine Kinase Inhibitor, has direct anti-firm
$\Lambda \cup \bot$	00 1	Yamamoto et al., "E7080 an Oral Multi-Targeted Tyrosine Kinase Inhibitor Has Direct Anti-Tumor 4038, 97th Annual Mactin Address in Gastrointestinal Stromal Tymor (CIST) in Address in Address in Castrointestinal Stromal Tymor (CIST) in Address in Address in Castrointestinal Stromal Tymor (CIST) in Address in Address in Address in Address in Castrointestinal Stromal Tymor (CIST) in Address in Address in Address in Address in Castrointestinal Stromal Tymor (CIST) in Address in Addre
MT 1	99   F	Efficacy via Inhibition of KIT Signaling in Gastrointestinal Stromal Tumor (GIST)," Abstract
<del>/-`-</del>	#	4038, 97th Annual Meeting AACP, West: Gastrointestinal Stromal Tumor (GIST)" Abstract
	100 €	4038, 97th Annual Meeting AACR, Washington, DC, April 1-5, 2006  NGLISH TRANSLATION)  NGLISH TRANSLATION
1/3	L	NGLISH TRANCIA TRANS
14	101 E	NGLISH TRANSLATION)  xaminer Elia Bonnevalle, Supplementary European Search Report in EP 04 81 8213 mailed 30
	, , , , , , , , , , , , , , , , , , ,	TENTRAL MANAGEMENT AND
<del></del>		nknown Korean Examiner, Notice Requesting Submission of Opinion in Application No. 10-2007- caminer D Margaret M Samuel State of Company of Com
	103 Ex	213993 mailed 31 July 2007, 9 pages (English translation)  Caminer D Margaret M Seaman, Non-Final Office Action in U.S. Serial No. 10/577,531 mailed 23  Examiner Anna Pagenship M.
<del></del>	Se	ptember 2008 17 pages, Non-Final Office Action in U.S. Serial No. 10/577 524
1 1	104 Ex	taminer Anna Pagonakis, Non-Final Office Action in U.S. Serial No. 10/797,903 mailed 20 aminer Anna Pagonakis.
-	Au	igust 2009 12 pages. Non-Final Office Action in U.S. Serial No. 10/707 202
1	LOS Ex	aminer Appa Pages 20
	$\frac{105}{\text{De}}$	aminer Anna Pagonakis, Non-Final Office Action in U.S. Serial No. 10/797,903 mailed 20 cember 2007, 12 pages
410 T	10 5 AII	thorized office M. 12 pages
11	106 1 . 20	MULLOU Ullicer Macachi II. 1
	17	thorized officer Masashi Honda, International Preliminary Report on Patentability in known Japanese Evaminary Communications of the Communication of the Com
	107 3 n	known Japanese Examiner. Office Action in Application No. P2005-516605 mailed 1 June 2010,
	P	1800 - 12005 516605 mailed 1-lung 2010

Examiner Signature			
		Date Considered	
EXAMINER: Initials cit next communication to	ation considered. Drawline through citation applicant.	if not in conformance and	2010.
	The state of the s		ered. Include copy of this form with
		S	Ubstitute Diester

Substitute Form PTO-1449 (Modified)  Information Discle by App (Use several shee	osure Statement	Attorney Docket No. 25142-0002001  Applicant Yamamoto et al.	Sheet _4_ of _5_ Application No. 10/797,903
(37 CFR §1.98(b))		Filing Date March 10, 2004	Group Art Unit 1628
Other Docume	nte linelude a		1020

	Other	Documents (include Author, Title, Date, and Place of Publication)
Examiner	Desig	. Title, Date, and Place of Publication
Initial		is of Tubilcation)
10	7.6	Anderson and Flora "P. Document
	76	Practice of Maria Preparation of Water-Soluble Compounds The
[		Anderson and Flora, "Preparation of Water-Soluble Compounds Through Salt Formation," The Clark et al., "Safety and Pharmacal."
ſ	77	Grand B. Safety and Pharmacokinetics of the Dual And B. Committee B. C
	[ ''	Clark et al., "Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothel Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid Furitsu and Suzuki, "Stable 100 pp. 739-754
	<del> </del>	Tumors," Clin Cancer Res, 2005, 11(15):5472-5480  Tumors, "Clin Cancer Res, 2005, 11(15):5472-5480  Tumors," Clin Cancer Res, 2005, 11(15):5472-5480
1	78	Furitsu and Suzuki, "Stable medicinal composition
	<del> </del> -	Furitsu and Suzuki, "Stable medicinal compositions of quinolinecarboxamide derivative," CAPLI Furuta et al., "Synthesis and Biological Evaluation of Selective Inhibition 2005, 2006, XP002520305
1	70	Furuta et al., "Synthesis and Riological Factorial Facto
	79	Furuta et al., "Synthesis and Biological Evaluation of Selective Inhibitors of PDGF Receptor Auto No. 64  Gardner et al. "In Vitro Activities of Post
		No. 64 No. 64
	80	Gardner et al., "In Vitro Activity of Sorghum-Selective Fluorophenyl Urea Herbicides," Pesticide Haleblian, "Characterinetic SV.
		Biochem Physiol 1085 24(2) 265 Sorghum-Selective Fluorophenyl Uroc II
1 1	01	Halehlian "Characteristic (43):285-297
	81	Pharmaceutical Application of Habits and Crystalline Modification as S. 111
1	00	Haleblian, "Characterization of Habits and Crystalline Modification of Solids and Their Hayek et al., "An In Vivo Model for Study of the A
	82	-100 Vi al. An in $1/100$ M. 1.0 $-1/100$ Vi $-1/1000$ Vi $-1/10000$ Vi $-1/10000$ Vi
		Hayek et al., "An In Vivo Model for Study of the Angiogenic Effects of Basic Fibroblast Growth  Jakeman et al., "Developmental Expression 238.
1	83	Vocant F. "Developmental Expression of Binding City
ĵ	0.5	Jakeman et al., "Developmental Expression of Binding Sites and Messenger Ribonucleic Acid for Vascular Endothelial Growth Factor Suggests a Role for This Protein in Vasculogenesis and Matsui et al. "E7080/EP 2007.
<del></del>	<del></del>	Angiogenesis," Endocrinology, 1993, 133(2):848-859  Matsui et al., "E7080/CR 203403 00)
į	04	Matsui et al., "E7080(ER-203492-00), a Novel VEGF Receptor Tyrosine Kinase Inhibitor-I.  2003
		Characterization as an Angiogenesis Inhibitor," Abstract #51, <u>AACR</u> , Toronto, Canada, April 5-9, Matsui et al., "E7080, a novel in it is in the state of the sta
	0.5	Matsui et al., "E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities inhibition, Int J Cancer 2008, 132-664, 671
	85	against stem cell factor producing by
	<u>i</u>	against stem cell factor producing human small cell lung cancer H146, based on angiogenesis Matsui et al. "F7080 a National Cell lung cancer H146, based on angiogenesis
	1	Matsui et al., "E7080, a Novel Multi-Receptor Tyrosine Kinases Inhibitor, Inhibited in vitro / in vivo Geneva, Switzerland, September 28.6
i l	86 7	VEGF- and SCF-driven Angiogenesis in SCLC Cell Line," Abstract #146, <u>EORTC-NCI-AACR</u> , Matsui et al. "Quantitative A. d.
	(	Geneva, Switzerland, September 28-October 1, 2004  Matsui et al., "Quantitative A. d.
j	1 1	Matsui et al. "Opportive" 28-October 1, 2004
1	87   B	Siomarkers for Ezono
	$\int \tilde{N}$	Matsui et al., "Quantitative Analysis of the Profile of Tumor Vessels may be Useful as Predictive Meeting, Los Angeles, CA, April 14-18, 2007  Matsui et al., "VEGERs inhibit." Profile of Tumor Vessels may be Useful as Predictive Meeting, Los Angeles, CA, April 14-18, 2007
	N	latsui et al. WEODB April 14-18, 2007
<b>,</b>	hy hy	Intsui et al., "VEGFRs inhibitor E7080 inhibits lymph node metastasis of human breast carcinoma, by preventing murine lymphatic endothelial cells from lymphangiogenesis." Abstract # PD 10.00
1	88   D)	th FORTO NEW lymphatic endothelial cells from lymph node metastasis of human breast carcinoma
		y preventing murine lymphatic endothelial cells from lymphangiogenesis," Abstract # PD12-8, zech Republic, November 7, 10, 2006.
	) M	Sth EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Prague, endel et al., "In Vivo Artitum of the Control of the Contr
1	1VI	endel et al., "In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase centoral Data.
	$\frac{10}{2}$	Honor Targeting Vascular Endothelial Growth Factor Tyrosine Kinase
{	Ke	hibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor  O3, 9:327-337
<del></del>	-120	sceptors: Determination of a Pharmacokinetic/Pharmacodynamic Relationship," Clin Cancer Res, yazaki et al., "Synthesis, Steptot
0~	Mi	yazaki et al., "Synthesis, Structure and Biological Activity Relationship of E7080 and its  GF Recentors, EGERAR
M / 1	90 De	rivatives as Novel and Potent Anti-
(D)	~ 12 l	on a wind total Antiangiogenic D
fr .	VE	GF Receptors FGFD 1 Dearth and Indian Prosing Kinggo Indian
P.	VE Jap	rivatives as Novel and Potent Antiangiogenic Protein Tyrosine Kinase Inhibitors Including the an, October 14-17, 2003  Structure and Biological Activity Relationship of E7080 and its FR Receptors, FGFR1 Receptor and PDGF Receptor, Abstract B-15, AIMECS03, Kyoto,

	<del>111, 2003</del>	AIMECS03, Kyoto,
Examiner Signature		
J. Samuel	Data Comment	
L. Comments	Date Considered	
EXAMINER: Initials citation considered. Draw lineart communication to applicant.		
next communication to next communication to	e through citation it	N12412010
applicant.	and a conformance and a	001 considered in
		to somsidered. Include copy of this form with
		<del></del>
		Substitute Disclass 5